Trial of High-Dose Oral Rifampin in Adults with Tuberculous Meningitis.

12 major claims checked against the paper's own evidence: all adequately supported.

Recomputed 5 tests: 5 consistent, 0 inconsistent, 5 via agent-written checks.

2 integrity concerns flagged (0 high).

11 copyedit issues flagged: mostly consistency, punctuation, typo.

Checked 33 references: 32 verified — 1 not checked.

1 data/code link checked; 0 live.

The paper is not ready for submission in its current form. The absence of a data availability statement (fail) and the generic ethics committee statement (warn) are critical reporting gaps that will likely be flagged by editors. The Table 1 inconsistency (count 144 but percentage 45.8%) must be corrected, and the implausibly optimistic power analysis should be acknowledged as a limitation. After these fixes and the other medium-priority actions (adding software name, exact p-values, manufacturer of drug), the paper would be ready for submission.

1. 1.
   HIGHdata code

   Add a data availability statement to the manuscript (e.g., after the Discussion or before References) specifying that de-identified individual participant data can be requested through a managed access process (e.g., corresponding author, data access committee, or platform like Vivli).

   A data availability statement is a journal requirement for clinical trials; its absence will cause the paper to be returned or rejected.
2. 2.
   HIGHethics

   In the Methods section, replace the generic 'Research ethics committees and relevant regulatory approvals occurred at all sites' with the name(s) of the specific ethics committee(s) that approved the study, including protocol/approval numbers for each site.

   Editors require traceable ethics approval; a generic statement is insufficient and may delay review or trigger a query.
3. 3.
   HIGHrigor

   Correct the inconsistency in Table 1 for the high-dose group 'Definite TBM' row: if the count is 144, the percentage should read 57.8% (144/249); if the percentage (45.8%) is correct, the count should be ~114. Verify the source data and correct the table.

   An internal numerical contradiction in a demographic table is a data-integrity issue that reviewers will catch and may raise concerns about data quality.
4. 4.
   HIGHreporting

   In the Discussion/Limitations section, add a sentence acknowledging that the trial was powered for a hazard ratio of 0.68, which is a large effect for a single drug-dose modification, and that the wide confidence interval (0.89 to 1.54) cannot exclude either a clinically meaningful benefit or harm.

   Transparency about the optimistic power assumption helps readers interpret the null result and prevents overstatement of the findings.
5. 5.
   HIGHstatistics

   In the Methods (Statistical Analysis), name the statistical software used (e.g., 'SAS version 9.4' or 'R version 4.3.2') and, if any custom code was used, provide a link to a repository (e.g., GitHub) or state that it is available upon request.

   Identifying the software is a standard reproducibility requirement; its absence is a common reviewer request.
6. 6.
   HIGHstatistics

   Report exact p-values (e.g., 'P=0.2532' instead of 'P=0.25') for the primary analysis and for all subgroup and secondary analyses, either in the Results text or as a supplementary table.

   Inexact p-values are less informative and can be misleading; exact values are standard for clinical trial reporting.
7. 7.
   HIGHreporting

   At the end of the Methods, add a statement that the trial was reported in accordance with CONSORT guidelines (cite the CONSORT 2010 statement), even though a CONSORT diagram already appears as Figure 1.

   Explicitly citing the reporting guideline is a CONSORT requirement and is expected by most journals.
8. 8.
   MEDIUMrigor

   In the Methods (Statistical Analysis), describe how the proportional hazards assumption for the Cox regression was tested (e.g., scaled Schoenfeld residuals) or state that it is assumed.

   Verifying assumptions of the primary model is a standard statistical practice; its omission may be noted by a statistical reviewer.
9. 9.
   MEDIUMrigor

   In the Methods (Intervention), add the manufacturer (and lot numbers if available) of the rifampicin and placebo tablets used in the trial.

   Identifying the source of the investigational product supports reproducibility and is required by many journals for drug trials.
10. 10.
    MEDIUMrigor

    In the Results or Table 1, consider reporting the race/ethnicity of participants as a supplementary demographic variable, if the data were collected.

    Race/ethnicity categories can be important for generalizability and are increasingly expected in clinical trial reporting.
11. 11.
    MEDIUMreporting

    In the Methods (Study Design), add an explicit statement that the trial was conducted in compliance with the Declaration of Helsinki and/or ICH-GCP guidelines.

    This formal regulatory compliance statement is expected by most journals and is a minor but missing detail.
12. 12.
    LOWcopyedit

    Correct typographical error: change 'interquartile rage' to 'interquartile range' in the Results (Secondary Outcomes).

    Minor typographical error.
13. 13.
    LOWcopyedit

    Correct 'permutated blocks' to 'permuted blocks' in the Methods (Randomization and Blinding).

    Standard statistical terminology.
14. 14.
    LOWcopyedit

    In the Abstract (Results), rephrase 'Excess mortality occurred with high-dose group among those...' to 'Excess mortality occurred in the high-dose group among those...' for grammatical correctness.

    Minor grammatical fix.
15. 15.
    LOWreporting

    In the Results (Subgroup Analyses), consider including the p-value for the subgroup comparison of mortality in patients receiving ART at baseline (HR=2.01, 95% CI 1.07 to 3.78).

    Adding the p-value improves completeness and clarity of subgroup reporting.